September 9, 2025

NOVONIX Appoints Kimberly Heimert as Chief Legal and Risk Officer

NOVONIX is pleased to announce the appointment of Kimberly Heimert as Chief Legal and Risk Officer. 

Ms. Heimert brings 30 years of global experience in private equity, debt finance, infrastructure investment, and clean energy. She has held senior legal and leadership roles across the public and private sectors, including serving as General Counsel of the Overseas Private Investment Corporation (now the U.S. DFC), General Counsel of Africa50, and Deputy Chief Counsel of the U.S. Department of Energy’s Loan Programs Office. Most recently, she was CEO of Energy Transition Advisory Group LLC, advising on critical minerals, infrastructure, and sustainable investment. 

Her extensive expertise in law, enterprise risk management, corporate governance, and sustainability will support NOVONIX’s continued growth and mission to commercialize a domestic and sustainable alternative to foreign-sourced graphite.

Explore more news

The Secret to Slashing Battery Test Times: Ultra-High Precision Coulometry (UHPC) and Machine Learning

Market Conditions Lead Axon Graphite to Withdraw IPO

NOVONIX Announces Entry into Funding Agreement for up to US$100 Million of Convertible Debentures

How UHPC Accelerated Research on Degradation Trends in LFP Cells: A Case Study with Eniko Zsoldos, PhD and Dalhousie University

The Secret to Slashing Battery Test Times: Ultra-High Precision Coulometry (UHPC) and Machine Learning

Published: August 7, 2025

Market Conditions Lead Axon Graphite to Withdraw IPO

Published: July 31, 2025

NOVONIX Announces Entry into Funding Agreement for up to US$100 Million of Convertible Debentures

Published: July 23, 2025

How UHPC Accelerated Research on Degradation Trends in LFP Cells: A Case Study with Eniko Zsoldos, PhD and Dalhousie University

Published: July 21, 2025

Catch Cell Degradation in Just Days

NOVONIX’s UHPC system detects the earliest signs of failure — down to the parts per million. Fill out the form to learn how we can accelerate your cell testing today.

"*" indicates required fields

By providing your email, you agree to receive updates and insights from NOVONIX. Unsubscribe at any time.